NCT07480681尚未招募1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (KAT6A/B Small Molecule Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
Shanghai Henlius Biotech0 个研究点目标入组 138 人开始时间: 2026年3月1日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 138
- 主要终点
- DLT
研究概览
简要总结
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic profiles, and preliminary efficacy of HLX97 ( KAT6A/B inhibitor) in patients with advanced/metastatic solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;
- •18-80 years of age, either sex;
- •Subjects who meet the corresponding requirements below will be enrolled.
- •Part 1A will enroll subjects with histologically or cytologically confirmed advanced/metastatic HR-positive, HER2-negative breast cancer (BC), castration-resistant prostate cancer (CRPC), or non-small cell lung cancer (NSCLC) who have failed standard therapy or for whom no standard therapy exists.
- •Part 1B will enroll subjects with histologically or cytologically confirmed advanced or metastatic HR-positive, HER2-negative breast cancer.
- •Part 2 will enroll subjects with histologically or cytologically confirmed advanced or metastatic HR-positive, HER2-negative breast cancer.
- •ECOG performance status of 0-1;
- •Life expectancy ≥ 12 weeks;
- •Adequate bone marrow and organ function.
排除标准
- •History of any second malignancy within 3 years prior to signing the ICF. Exceptions include early-stage malignancies (carcinoma in situ or Stage I tumors) that have been curatively treated, such as non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, ductal carcinoma in situ of the breast, or papillary thyroid cancer.
- •Active systemic infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to the first dose.
- •Subjects with poorly controlled clinical symptoms or diseases of the cardiovascular and cerebrovascular system, including but not limited to:
- •NYHA Class ≥II heart failure or left ventricular ejection fraction (LVEF) < 50%; Unstable angina; Myocardial infarction or cerebrovascular accident within 6 months (excluding lacunar infarction, minor cerebral ischemia, or transient ischemic attack); Poorly controlled arrhythmias (including QTc interval ≥450 ms for males or ≥470 ms for females, calculated using the Fridericia formula); Poorly controlled hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg despite active treatment).
- •Presence of spinal cord compression or clinically symptomatic central nervous system (CNS) metastases, defined as untreated, symptomatic, or requiring corticosteroids or anticonvulsants to control symptoms. Subjects with stable brain metastases may be included. Subjects with previously diagnosed brain metastases are eligible if they have completed treatment, have recovered from the acute effects of radiotherapy or surgery prior to enrollment, have discontinued corticosteroid therapy for these metastases for at least 3 weeks, and are neurologically stable for 2 months (requiring MRI confirmation).
- •Presence of residual toxicity from prior anti-tumor therapy that has not resolved, defined as toxicity not resolved to Grade ≤1 or baseline levels per CTCAE V5.0 (alopecia excepted).
- •Note: Subjects with chronic, stable Grade 2 toxicity deemed by the investigator to be related to prior anti-tumor therapy (defined as no worsening to ≥ Grade 2 for at least 3 months prior to enrollment and managed with standard medical measures) may be enrolled; for example: chemotherapy-induced neuropathy, fatigue, and residual toxicity from prior immunotherapy (Grade 1 or 2 endocrinopathies, which may include hypothyroidism/hyperthyroidism, Type 1 diabetes mellitus, hyperglycemia, adrenal insufficiency, adrenalitis, skin hypopigmentation/vitiligo).
- •Prior radiotherapy to bone marrow involving >25% of the total bone marrow volume (e.g., prior whole pelvic radiotherapy, whole spine radiotherapy, etc.; excluding local radiotherapy to single or a few vertebral bodies, local radiotherapy to the chest wall, etc.).
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage (defined as requiring drainage at least once monthly).
- •Use of therapeutic anticoagulants. Low molecular weight heparin is permitted. Use of vitamin K antagonists or Factor Xa inhibitors may be permitted after discussion with the sponsor.
- •Active inflammatory gastrointestinal disease, refractory or unresolved chronic diarrhea, or history of gastrectomy, gastric banding surgery, or other gastrointestinal conditions or surgeries that could significantly alter the absorption of HLX97 tablets. Treated gastroesophageal reflux disease is permitted.
- •Patients who received systemic corticosteroids (prednisone ≥10 mg/day or equivalent dose of similar medication) or other immunosuppressive agents within 14 days prior to the first dose.
研究组 & 干预措施
Dose Escalation（Single）
Experimental
A total of 5 dose escalations were preset: Dose1, Dose2, Dose3, Dose4, Dose5
干预措施: HLX97 (Drug)
Dose Escalation（in combination with Fulv）
Experimental
A total of 3 dose escalations were preset: Dose1, Dose2, Dose3
干预措施: HLX97 (Drug)
Dose Escalation（in combination with Fulv）
Experimental
A total of 3 dose escalations were preset: Dose1, Dose2, Dose3
干预措施: Fulvestrant (Drug)
结局指标
主要结局
DLT
时间窗: From first dose to the end of Cycle 1 (each cycle is 4 weeks)
DLT refers to the AEs that are determined to be related to the investigational product by the investigator, whose severity will affect the escalation of dose level. In this study, the DLT observation period lasts for 28 days after the first administration of HLX97.
MTD
时间窗: From first dose to the end of Cycle 1 (each cycle is 4 weeks)
the highest dose level, at which DLT is observed in no more than one of 6 evaluable patients, is defined as MTD of HLX97
ORR
时间窗: approximately up to 24 months
Percentage of participants with complete response (CR) and partial response (PR) based on investigator assessment.
PFS
时间窗: approximately up to 24 months.
The PFS is defined as the time from the date of enrollment to the date of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause,whichever occurred first.
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical CystectomyNCT07468851Jiangsu Hansoh Pharmaceutical Co., Ltd.180
尚未招募
1 期
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNCT07279428Sichuan Baili Pharmaceutical Co., Ltd.33
暂停
2 期
ARN-75039 Lassa Fever Treatment in West AfricaLassa FeverNCT07419373Arisan Therapeutics, Inc.135
招募中
2 期
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid TumorsNCT07480733Shanghai Junshi Bioscience Co., Ltd.410
尚未招募
1 期
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant TumorsNCT07475559Jiangsu Alphamab Biopharmaceuticals Co., Ltd42